<th id="grzca"></th>
<b id="grzca"><menuitem id="grzca"></menuitem></b>

<th id="grzca"></th>
<strong id="grzca"><form id="grzca"></form></strong>
  • <del id="grzca"><form id="grzca"></form></del>

    全國服務咨詢熱線:

    18438616290

    Products產品中心
    首頁 > 產品中心 > 生化試劑 > 小分子化合物 > abs47027704Adriamycin 23214-92-8

    Adriamycin 23214-92-8

    簡要描述:Adriamycin 23214-92-8
    Doxorubicin is an Anthracycline Topoisomerase Inhibitor. The mechanism of action of doxorubicin is as a Topoisomerase Inhibitor.

    • 產品型號:abs47027704
    • 廠商性質:生產廠家
    • 更新時間:2025-12-25
    • 訪  問  量:567

    詳細介紹

    品牌absinCAS23214-92-8
    分子式C27H29NO11純度98%
    分子量543.52貨號abs47027704
    規(guī)格10mg供貨周期現貨
    主要用途is an Anthracycline Topoisomerase Inhibi應用領域化工,生物產業(yè),農林牧漁,制藥/生物制藥,綜合

    Adriamycin 23214-92-8

    產品描述
    描述

    Doxorubicin is an Anthracycline Topoisomerase Inhibitor. The mechanism of action of doxorubicin is as a Topoisomerase Inhibitor. The chemical classification of doxorubicin is Anthracyclines.

    純度
    98%
    儲存/保存方法
    Store at -20℃ for three years(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.
    基本信息
    別名
    阿mei素;多柔bi星;Doxorubicin
    外觀
    Orange to red powder
    可溶性/溶解性
    10 mM in DMSO
    生物活性
    In vitro(體外研究)
    Combination of Doxorubicin and Simvastatin in the highest tested concentrations (2 μM and 10 μM, respec-tively) kills 97% of the Hela cells.
    In vivo(體內研究)
    Mice bearing PC3 xenografts are injected with 2, 4 or 8 mg/kg Doxorubicin and tumor volume is measured over time. A dose of 2 mg/kg does not affect tumor growth while higher dosages delay tumor growth initially (p<0.05 at days 18 and 22), 4 mg/kg or 8 mg/kg Doxorubicin significantly reduces levels of c-FLIP in PC3 xenografts. A single intraperitoneal injection 10 mg/kg (Doxorubicin 1) is administered in rats, 10 daily intraperitoneal injections of 1 mg/kg (Doxorubicin 2), or in 5 weekly intraperitoneal injections of 2 mg/kg (Doxorubicin 3). An 80% mortality rate is observed at day 28 in Doxorubicin 1, whereas Doxorubicin 2 and Doxorubicin 3 reached 80% mortality at days 107 and 98, respectively. Fractional shortening decreased by 30% at week 2 in Doxorubicin DOX1, 55% at week 13 in Doxorubicin 2, and 42% at week 13 in Doxorubicin 3.
    研究領域
    研究領域
    CancerTumor biomarkers
    CancerTumor immunology
    MetabolismTypes of disease
    Drug DiscoverySmall Molecule DrugLead Compound Discovery
    Adriamycin 23214-92-8溫馨提示:本產品僅作科研實驗使用,不支持臨床等研究

    產品咨詢

    留言框

    • 產品:

    • 您的單位:

    • 您的姓名:

    • 聯(lián)系電話:

    • 常用郵箱:

    • 省份:

    • 詳細地址:

    • 補充說明:

    • 驗證碼:

      請輸入計算結果(填寫阿拉伯數字),如:三加四=7
    愛必信(上海)生物科技有限公司
    地址:上海市浦東新區(qū)新浩路58號申江科創(chuàng)園18棟
    傳真:
    關注我們
    歡迎您關注我們的微信公眾號了解更多信息:
    歡迎您關注我們的微信公眾號
    了解更多信息
    <th id="grzca"></th>
    <b id="grzca"><menuitem id="grzca"></menuitem></b>

    <th id="grzca"></th>
    <strong id="grzca"><form id="grzca"></form></strong>
  • <del id="grzca"><form id="grzca"></form></del>

    亚洲 小说区 图片区 都市 | 淫色人妻一区二区三区 | 青青自拍视频免费观看 | 日韩性爱在线电影网 | 欧美日韩性爱一区二区三区 |